PLK1-mediated phosphorylation of PHGDH reprograms serine metabolism in advanced prostate cancer

Xiongjian Rao, Derek B. Allison, Robert M Flight, Penghui Lin, Daheng He, Zhiguo Li, Yanquan Zhang, Ruixin Wang, Chaohao Li, Jianlin Wang, Xiaonan Wang, Peng Jia, Ka-wing Fong, Qing Shao, Chi Wang, Eunüs S. Ali, Hunter Moseley, Xiaoqi LiubioRxiv 2025 · DOI

TL;DR

This study reveals a novel mechanism where the kinase PLK1 phosphorylates and degrades PHGDH, a key enzyme in serine synthesis. This forces prostate cancer cells to rely on external serine for lipid production, offering new therapeutic targets for advanced prostate cancer.

What Problem Does This Paper Address?

Cancer cells are notorious for their metabolic flexibility, reprogramming their nutrient utilization to fuel rapid growth and survival. Serine metabolism is particularly crucial, with many cancer cells becoming dependent on external serine uptake rather than producing it themselves. However, the precise regulatory mechanisms behind this dependency, especially in aggressive cancers like advanced prostate cancer, remain unclear. This paper aims to elucidate how Polo-like kinase 1 (PLK1), a protein often overexpressed in prostate cancer, influences serine metabolism and contributes to tumor progression.

Methods

The researchers employed a multi-pronged approach:

  • Western Blotting (WB): To assess protein levels of key enzymes and transporters involved in serine and lipid metabolism.
  • Lipidomics: Using Direct Infusion Fourier Transform Mass Spectrometry (DI-FTMS) to analyze and quantify various lipid species in cells.
  • Immunoprecipitation (IP): To investigate the physical interaction between PLK1 and PHGDH.
  • In vitro Kinase Assays: To determine if PLK1 can directly phosphorylate PHGDH and to identify specific phosphorylation sites.
  • Site-Directed Mutagenesis: To create mutant forms of PHGDH (e.g., alanine substitutions at phosphorylation sites) to study the functional consequences of phosphorylation.
  • Enzyme Activity Assays: To measure the enzymatic activity of PHGDH under different conditions.
  • Metabolic Labeling Studies: Using stable isotope-labeled glucose and serine ([U-13C]-Glucose and [2,3,3-2H]-serine) to trace metabolic flux through various pathways.
  • NMR Spectroscopy: To analyze the metabolic profiles of cells and media.
  • Molecular Dynamics (MD) Simulations: To model the structural changes in PHGDH upon phosphorylation.
  • Cell-based Assays: Including colony formation assays and cell viability assays to assess the impact of metabolic changes on cancer cell growth and survival.
  • In vivo Xenograft Models: To study the effects of PLK1 and PHGDH manipulation in a living organism.
  • Bioinformatic Analysis: Including TCGA data analysis for gene expression and survival probability correlations.

Datasets

  • TCGA-PRAD (Prostate Adenocarcinoma) RNA-Seq data: Used for analyzing gene expression patterns of PLK1 and PHGDH in prostate cancer.
  • Human Prostate Biopsies (TMA): Used for immunohistochemistry (IHC) analysis of PLK1 and PHGDH expression.
  • Patient-Derived Xenografts (PDXs): Used for assessing enzyme expression in advanced prostate cancer.

Key Insights and Ideas

  • PLK1 as a metabolic regulator: Beyond its known role in cell cycle control, PLK1 actively reprograms cancer cell metabolism, specifically targeting serine and lipid pathways.
  • PHGDH phosphorylation as a degradation signal: PLK1 doesn't just inhibit PHGDH; it phosphorylates it at specific sites (S512, S513, S517), marking it for degradation and reducing its protein levels. This is a crucial step in shifting the metabolic balance.
  • Forced reliance on exogenous serine: By downregulating de novo serine synthesis, PLK1 creates a dependency on external serine uptake, highlighting a vulnerability that can be exploited.
  • Sphingolipid synthesis as a key downstream target: The increased uptake of exogenous serine is channeled into the synthesis of lipids, particularly sphingolipids, which are essential for tumor growth and survival.
  • ASCT2 as a critical transporter: PLK1 upregulates the ASCT2 transporter, which is responsible for serine uptake, further reinforcing the shift towards exogenous serine.

Key Results

  • PLK1 overexpression in prostate cancer cells leads to a significant increase in sphingolipid abundance.
  • PLK1 phosphorylates PHGDH at S512, S513, and S517, leading to decreased PHGDH protein levels and enzymatic activity.
  • Knocking down PLK1 increases PHGDH levels, while overexpressing PLK1 decreases them.
  • PLK1 overexpression significantly increases exogenous serine uptake, primarily mediated by the ASCT2 transporter.
  • In vivo studies using a mouse model showed that PHGDH phosphorylation leads to increased fat accumulation.
  • Combination therapies targeting PLK1 and PHGDH inhibitors showed promising results in blocking prostate cancer growth.

Limitations and Future Work

  • Serine and Glycine Measurement Sensitivity: The high salt content in samples affected the sensitivity of serine and glycine measurements by ESI-MS, limiting precise quantification.
  • Phospho-specific Antibody Sensitivity: The sensitivity of phospho-specific antibodies for PHGDH at S512 and S513 was insufficient for robust detection of phosphorylated PHGDH.
  • Molecular Mechanism of PHGDH Downregulation: The precise molecular mechanism behind PHGDH downregulation in response to elevated PLK1 expression remains unclear.
  • Serine/Glycine-Deficient Diet Studies: Further studies are needed to assess the effects of a serine/glycine-deficient diet in PHGDH-2D mice.
  • Fat Tissue Composition Verification: Further mass spectrometry studies are required to verify the fat tissue composition in vivo.

The authors suggest that targeting PLK1-mediated metabolic pathways, including the serine synthesis pathway, serine uptake, and downstream lipid biosynthesis, holds therapeutic potential for advanced prostate cancers.

Summary updated

Abstract

Metabolic reprogramming is a hallmark of cancer, enabling tumor cells to meet their increased biosynthetic and energetic demands. While cells possess the capacity for de novo serine biosynthesis, most transformed cancer cells heavily depend on exogenous serine uptake to sustain their growth, yet the regulatory mechanisms driving this metabolic dependency remain poorly understood. Here, we uncover a novel mechanism by which Polo-like kinase 1 (PLK1), often overexpressed in prostate cancer, orchestrates a metabolic shift in serine and lipid metabolism through the phosphorylation of phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme of the serine synthesis pathway (SSP). We demonstrate that PLK1 phosphorylates PHGDH at three specific sites (S512, S513, S517), leading to a marked reduction in its protein level and enzymatic activity. This downregulation of SSP forces cancer cells to increase their reliance on exogenous serine uptake via the ASCT2 transporter, which, in turn, fuels the biosynthesis of lipids, including sphingolipids essential for tumor growth and survival. Targeting the SSP, serine uptake, or downstream lipid biosynthetic pathways may offer promising therapeutic avenues in PLK1-high advanced cancers.
BibTeX
@misc{rao2025plk,
  author = {Xiongjian Rao and Derek B. Allison and Robert M Flight and Penghui Lin and Daheng He and Zhiguo Li and Yanquan Zhang and Ruixin Wang and Chaohao Li and Jianlin Wang and Xiaonan Wang and Peng Jia and Ka-wing Fong and Qing Shao and Chi Wang and Eunüs S. Ali and Hunter Moseley and Xiaoqi Liu},
  title = {{PLK1-mediated phosphorylation of PHGDH reprograms serine metabolism in advanced prostate cancer}},
  year = {2025},
  doi = {10.1101/2025.05.21.655274},
  howpublished = {bioRxiv},
}
Figure